Literature DB >> 29077971

Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma.

Hanna Lythgoe1,2,3, Eileen Baildam1, Michael W Beresford1,2,3, Gavin Cleary1, Liza J McCann1, Clare E Pain1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29077971     DOI： 10.1093/rheumatology/kex382

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  5 in total

Review 1.  Overview of Juvenile localized scleroderma and its management.

Authors:  Suzanne C Li; Rong-Jun Zheng
Journal:  World J Pediatr       Date:  2019-11-30       Impact factor: 2.764

Review 2.  Is biological therapy in systemic sclerosis the answer?

Authors:  Durga Prasanna Misra; Sakir Ahmed; Vikas Agarwal
Journal:  Rheumatol Int       Date:  2020-01-20       Impact factor: 2.631

3.  Multi-centre national audit of juvenile localised scleroderma: describing current UK practice in disease assessment and management.

Authors:  Hanna Lythgoe; Beverley Almeida; Joshua Bennett; Chandrika Bhat; Amarpal Bilkhu; Mary Brennan; Samundeeswari Deepak; Pamela Dawson; Despina Eleftheriou; Kathryn Harrison; Daniel Hawley; Eleanor Heaf; Valentina Leone; Ema Long; Sarah Maltby; Flora McErlane; Nadia Rafiq; Athimalaipet V Ramanan; Phil Riley; Satyapal Rangaraj; Giulia Varnier; Nick Wilkinson; Clare E Pain
Journal:  Pediatr Rheumatol Online J       Date:  2018-12-18       Impact factor: 3.054

4.  Consensus-based recommendations for the management of juvenile localised scleroderma.

Authors:  Francesco Zulian; Roberta Culpo; Francesca Sperotto; Jordi Anton; Tadej Avcin; Eileen M Baildam; Christina Boros; Jeffrey Chaitow; Tamàs Constantin; Ozgur Kasapcopur; Sheila Knupp Feitosa de Oliveira; Clarissa A Pilkington; Ricardo Russo; Natasa Toplak; Annet van Royen; Claudia Saad Magalhães; Sebastiaan J Vastert; Nico M Wulffraat; Ivan Foeldvari
Journal:  Ann Rheum Dis       Date:  2019-03-02       Impact factor: 19.103

5.  Mycophenolate mofetil for methotrexate-resistant juvenile localized scleroderma.

Authors:  Giorgia Martini; Laura Saggioro; Roberta Culpo; Fabio Vittadello; Alessandra Meneghel; Francesco Zulian
Journal:  Rheumatology (Oxford)       Date:  2021-03-02       Impact factor: 7.580
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.